Acorda's only drug on the market is Zanaflex, a muscle relaxant. The company has two other drug candidates in preclinical development, and a third in the ...
He foresees earnings of 90 cents a share in 2010, based on early Fampridine sales and revenue from Acorda's only other product, Zanaflex, which helps MS ...
The Company's marketed products include Zanaflex Capsules, a short-acting drug for the management of spasticity. Acorda is conducting a Phase 3 clinical ...
"In addition, we were pleased with the continued growth of our Zanaflex business. Based on our current projections, we expect our Zanaflex commercial ...
The Company's marketed products include Zanaflex Capsules™ (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ...
Sequence of avoided if zanaflex isolated from zanamivir trial is zankiren intubation. This might medical records licenses issued zanosar ingredient or ...
The Company's marketed products include Zanaflex Capsules™ (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ...
... the name "Melissa Anderson" to acquire hydrocodone and zanaflex from a Turtle Lake drugstore; the name "Allison Hendrickson" to acquire hydrocodone and ...
... the company reported. sales were up to $10.44 million from $6.16 million. acorda markets zanaflex, a treatment for involuntary muscle movements caused ...
... the name "Melissa Anderson" to acquire hydrocodone and zanaflex from a Turtle Lake drugstore; the name "Allison Hendrickson" to acquire hydrocodone and ...